Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having a C.sub.max to C.sub.min ratio of less than 200 and a lag time less than 0.2.

The present disclosure relates to a solution comprising a water insoluble carbohydrate and a fluorescent dye, such as a near infrared (NIR) contrast agent, wherein the solution sets under aqueous conditions, such as in vivo, to form e.g. a gel, a glass, a semi-solid, a solid, a crystal or any mixtures thereof. The disclosure further relates to preparation of such solution and use of such solution for in vivo imaging and/or guidance of surgery or interventional therapeutic procedures.

Compositions comprising a red blood cell (RBC) having non-toxically coupled thereto a nanoparticle having a low shear modulus or low Young's modulus of less than 10 MPa and containing a drug are provided. In one embodiment, the nanoparticles are optionally coated with protein. In another embodiment, the nanoparticle has no cell-specific targeting moiety or tissue-specific targeting moiety or organ-specific targeting moiety associated therewith. Methods of delivering selected drugs to target organs use these compositions both in vivo and ex vivo treatment of disease and for imaging.

Provided herein are kits, compositions, and methods for treatment of a disease, disorder, or condition, such as a proliferative disease, disorder, or condition. One aspect provides a composition including a radioisotope, a gelatin matrix and bovine collagen or a thixotropic gel. Another aspect provides methods for treating a disease, disorder, or condition.

The invention provides a compound having the following structure:

T-DOTA-R,

wherein T is a carbohydrate polymer, R is a radioactive isotope, DOTA is a chelator of R, and T is covalently bond to DOTA. In one embodiment, the carbohydrate polymer is hyaluronic acid (HA). The compound or HA is used alone as a polymer or incorporated into a hydrogel for treating body cavity cancer, comprising administering an effective amount of the compound or hydrogel. The invention also provides a method for treating body cavity or soft tissue cancer comprising: introducing into the affected area a thermo reversible gel comprising the compound or HA, allowing the radioactive isotope to emit a therapeutic radiation to affected regions; and, after a predetermined time, optionally removing the gel from the body cavity with a cold rinse to liquefy the gel and allow it to exit the body cavity.

Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.

In some aspects, the present disclosure pertains to a polymer that comprises a plurality of polymer arms, wherein a first portion of the polymer arms comprise a reactive end group and wherein a second portion of the polymer arms comprise a branched end group that comprise a plurality of covalently attached diagnostic and/or therapeutic groups, which may be, for example, radiocontrast groups or radioactive groups. Other aspects pertain to a system that comprises (a) a first composition comprising such a polymer and (b) a second composition comprising a multifunctional compound that comprises reactive functional groups that are reactive with the reactive end group of the multi-arm polymer. Still other aspects pertain to a crosslinked reaction product of (a) such a polymer and (b) a multifunctional compound that comprises functional groups that are reactive with the reactive end group of the multi-arm polymer.